Covidien's clot-prevention device shows positive trial results

06/24/2013 | American City Business Journals

A study appearing in The Lancet found that Covidien's Kendall SCD device reduced the risk of blood clots by 30% and cut mortality rate by 14% in immobile stroke patients. The device, which gained U.S. approval in 2004, is designed to help minimize proximal deep vein thrombosis in stroke patients by applying limb pressure.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR